A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 2 of 12 entries
    • Site details revised
  2. Study sites: 0 to 1v4
  3. Start date: Jun 30, 2026 to Aug 17, 2026v3
  4. Start date: Jun 15, 2026 to Jun 30, 2026v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
410 trials monitored
See 27 trials at risk
This study is designed to determine the effect of ulonivirine (MK-8507) on methadone in the body. Participants will take methadone alone and then methadone with ulonivirine to see if ulonivirine changes how the body processes methadone.
Trial Details
NCT Number NCT07595263
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Healthy
Enrollment 14 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov